In vitro and in vivo activities of a new lead compound I2906 against Mycobacterium tuberculosis

Pharmacology

Volumn 85, Issue 6, 2010, Pages 365-371

  Lu, Jingning ^a   Yue, Jun ^b   Wu, Jing ^a   Luo, Rusong ^a   Hu, Zhidong ^a   Li, Jianrong ^c   Bai, Yun ^c   Tang, Zhijiao ^d   Xian, Qiaoyang ^d   Zhang, Xuelian ^a   Wang, Honghai ^a  

^a FUDAN UNIVERSITY   (China)

^b SHANGHAI PULMONARY HOSPITAL   (China)

^c HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^d WUHAN UNIVERSITY   (China)

Author keywords

Antimycobacterial activity; Murine model; Tuberculosis

Indexed keywords

I 2906; ISONIAZID; RIFAMPICIN; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG; 1-ETHYL-4-HYDROXY-2-OXO-N'-TRIDECANOYL-1,2-DIHYDROQUINOLINE-3-CARBOHYDRAZIDE; HYDRAZINE DERIVATIVE; QUINOLONE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL COUNT; BACTERIAL STRAIN; COLONY FORMING UNIT; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENTIATION; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; LOW DRUG DOSE; LUNG TUBERCULOSIS; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; MOUSE; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; SURVIVAL RATE; ANIMAL; BAGG ALBINO MOUSE; BLOOD; DRUG EFFECTS; DRUG SCREENING; GROWTH, DEVELOPMENT AND AGING; HAPLORHINI; LUNG; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; PATHOGENICITY; PATHOLOGY; SPLEEN; SURVIVAL; TOXICITY; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY; TUMOR CELL LINE;

ANIMALS; ANTITUBERCULAR AGENTS; CELL LINE, TUMOR; COLONY COUNT, MICROBIAL; DRUG EVALUATION, PRECLINICAL; FEMALE; HAPLORHINI; HUMANS; HYDRAZINES; ISONIAZID; LUNG; MICE; MICE, INBRED BALB C; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; QUINOLONES; SPLEEN; SURVIVAL ANALYSIS; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY;

EID: 77953125331     PISSN: 00317012     EISSN: None     Source Type: Journal    
DOI: 10.1159/000299795     Document Type: Article

References (12)

1. Global Alliance for TB Drug Development: Developing a faster TB cure. 2004; www. tballiance.org.
2. O'Brien RJ, Nunn PP: The need for new drugs against tuberculosis. Am J Respir Crit Care Med 2001; 163: 1055-1058.
3. Centers for Disease Control and Prevention (CDC): Plan to combat extensively drug-resistant tuberculosis: recommendations of the Federal Tuberculosis Task Force. MMWR Recomm Rep 2009; 58: 1-43.
4. Bentrup KHZ, Miczak A, Swenson DL, Russell DG: Characterization of activity and expression of isocitrate lyase in Mycobacterium avium and Mycobacterium tuberculosis . J Bacteriol 1999; 181: 7161-7167.
5. Sharma V, Sharma S, Bentrup KHZ, Mckinney JD, Russell DG, Jacobs JWR, Sacchettini JC: Structure of isocitrate lyase, a persistence factor of mycobacterium tuberculosis. Nat Struct Biol 2000; 7: 663-668.
6. Bai B, Xie JP, Yan JF, Wang HH, Hu CH: A high throughput screening approach to identify isocitrate lyase inhibitors from traditional Chinese medicine sources. Drug Dev Res 2006; 67: 818-823.
7. Falzari K, Zhu ZH, Pan DH, Liu HW, Hongmanee P, Franzblau SG: In vitro and in vivo activities of macrolide derivatives against Mycobacterium tuberculosis . Antimicrob Agents Chemother 2005; 49: 1447-1454.
8. Shen HB, Wang FF, Zhang Y, Huang Q, Xu SF, Hu HR, Yue J, Wang HH: A novel inhibitor of indole-3-glycerol phosphate synthase with activity against multidrug-resistant Mycobacterium tuberculosis . FEBS J 2009; 276: 144-154.
9. Siddiqi SH, Libonati JP, Middlebrook G: Evaluation of rapid radiometric method for drug susceptibility testing of Mycobacterium tuberculosis . J Clin Microbiol 1981; 13: 908-912.
10. Kradolfer F: Rifampicin, isoniazid, ethambutol, ethionamide, and streptomycin in murine tuberculosis: comparative chemotherapeutic studies. Antibiot Chemother (Basel) 1970; 16: 352-360.
11. Ji BH, Lounis N, Maslo C, Truffot-Pernot C, Bonnafous P, Grosset J: In vitro and in vivo activities of moxifloxacin and clinafloxacin against Mycobacterium tuberculosis . Antimicrob Agents Chemother 1998; 42: 2066-2069.
12. Oleksijew A, Meulbroek J, Ewing P, Jarvis K, Mitten M, Paige L, Tovcimak A, Nukkula M, Chu D, Alder JD: In vivo efficacy of ABT-255 against drug-sensitive and -resistant Mycobacterium tuberculosis strains. Antimicrob Agents Chemother 1998; 42: 2674-2677.